35,376 results match your criteria Glioblastoma Multiforme* Neurology


MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44.

J Neurooncol 2018 Dec 11. Epub 2018 Dec 11.

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, People's Republic of China.

Background: Glioblastoma (GBM) is the most common malignant tumor originating in the brain parenchyma. The invasive and infiltrative properties of glioblastoma result in poor clinical prognosis to conventional therapies. Emerging reports on microRNAs as important regulators during the process of EMT provide new insights into treating glioblastoma through new targets. Read More

View Article
December 2018

Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme.

Oncolytic Virother 2018 19;7:107-116. Epub 2018 Nov 19.

Department of Microbiology and Immunology, Medical University of South Carolina, SC, USA,

Background: Glioblastoma multiforme (GBM) is an aggressive form of brain cancer which is associated with poor prognosis. A variety of oncolytic viruses have previously shown positive efficacy against GBM, potentially offering new treatment options for patients. One such oncolytic virus is Myxoma virus (MYXV), a rabbit-specific poxvirus that has been shown to be efficacious against a variety of tumor models including GBM. Read More

View Article
November 2018

The proneural gene ASCL1 governs the transcriptional subgroup affiliation in glioblastoma stem cells by directly repressing the mesenchymal gene NDRG1.

Cell Death Differ 2018 Dec 11. Epub 2018 Dec 11.

Neural Stem Cell Biology Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.

Achaete-scute homolog 1 gene (ASCL1) is a gene classifier for the proneural (PN) transcriptional subgroup of glioblastoma (GBM) that has a relevant role in the neuronal-like differentiation of GBM cancer stem cells (CSCs) through the activation of a PN gene signature. Besides prototypical ASCL1 PN target genes, the molecular effectors mediating ASCL1 function in regulating GBM differentiation and, most relevantly, subgroup specification are currently unknown. Here we report that ASCL1 not only promotes the acquisition of a PN phenotype in CSCs by inducing a glial-to-neuronal lineage switch but also concomitantly represses mesenchymal (MES) features by directly downregulating the expression of N-Myc downstream-regulated gene 1 (NDRG1), which we propose as a novel gene classifier of MES GBMs. Read More

View Article
December 2018

ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.

Cell Death Dis 2018 Dec 11;9(12):1190. Epub 2018 Dec 11.

Chinese Glioma Genome Atlas Network(CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China.

As aldehyde dehydrogenase (ALDH) is a novel stem cell marker, increasing studies have confirmed that high ALDH activity promotes tumorigenesis and progression in cancers. Some preliminary studies have found that ALDH1A3 may play an important role in glioma malignant progression, but so far there was no conclusive conclusion. The purpose of our study was to elucidate the mechanisms by which ALDH1A3 regulated in glioma and to provide practical tools for clinical application. Read More

View Article
December 2018
1 Read

Apurinic endonuclease-1 preserves neural genome integrity to maintain homeostasis and thermoregulation and prevent brain tumors.

Proc Natl Acad Sci U S A 2018 Dec 11. Epub 2018 Dec 11.

Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN 38105;

Frequent oxidative modification of the neural genome is a by-product of the high oxygen consumption of the nervous system. Rapid correction of oxidative DNA lesions is essential, as genome stability is a paramount determinant of neural homeostasis. Apurinic/apyrimidinic endonuclease 1 (APE1; also known as "APEX1" or "REF1") is a key enzyme for the repair of oxidative DNA damage, although the specific role(s) for this enzyme in the development and maintenance of the nervous system is largely unknown. Read More

View Article
December 2018

Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.

J Colloid Interface Sci 2018 Dec 4;538:449-461. Epub 2018 Dec 4.

Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy; Politecnico di Torino, Department of Mechanical and Aerospace Engineering, Corso Duca degli Abruzzi 24, 10129 Torino, Italy. Electronic address:

Major obstacles to the successful treatment of gliolastoma multiforme are mostly related to the acquired resistance to chemotherapy drugs and, after surgery, to the cancer recurrence in correspondence of residual microscopic foci. As innovative anticancer approach, low-intensity electric stimulation represents a physical treatment able to reduce multidrug resistance of cancer and to induce remarkable anti-proliferative effects by interfering with Ca and K homeostasis and by affecting the organization of the mitotic spindles. However, to preserve healthy cells, it is utterly important to direct the electric stimuli only to malignant cells. Read More

View Article
December 2018
1 Read

Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.

J Control Release 2018 Dec 8. Epub 2018 Dec 8.

Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5, 8093 Zurich, Switzerland.

In glioblastoma, the benefit from temozolomide chemotherapy is largely limited to a subgroup of patients (30-35%) with tumors exhibiting methylation of the promoter region of the O-methylguanine-DNA methyltransferase (MGMT) gene. In order to allow more patients to benefit from this treatment, we explored magnetic resonance image-guided microbubble-enhanced low-intensity pulsed focused ultrasound (LIFU) to transiently open the blood-brain barrier and deliver a first-in-class liposome-loaded small molecule MGMT inactivator in mice bearing temozolomide-resistant gliomas. We demonstrate that a liposomal O-(4-bromothenyl)guanine (OBTG) derivative can efficiently target MGMT, thereby sensitizing murine and human glioma cells to temozolomide in vitro. Read More

View Article
December 2018
7.705 Impact Factor

Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth.

Adv Healthc Mater 2018 Dec 11:e1801076. Epub 2018 Dec 11.

Department of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC, 27705, USA.

Brain tumors remain a great clinical challenge, in part due to their capacity to invade into eloquent, inoperable regions of the brain. In contrast, inflammation in the central nervous system (CNS) due to injuries activates microglia and astrocytes culminating in an astroglial scar that typically "walls-off" the injury site. Here, the hypothesis is tested that targeting peritumoral cells surrounding tumors to activate them via an inflammatory stimulus that recapitulates the sequelae of a traumatic CNS injury, could generate an environment that would wall-off and contain invasive tumors in the brain. Read More

View Article
December 2018
1 Read

Diacylglycerol kinase α-selective inhibitors induce apoptosis and reduce viability of melanoma and several other cancer cell lines.

J Cell Biochem 2018 Dec 9. Epub 2018 Dec 9.

Department of Chemistry, Graduate School of Science, Chiba University, Chiba, Japan.

Diacylglycerol (DG) kinase (DGK), which phosphorylates DG to generate phosphatidic acid (PA), consists of ten isozymes (α-к). Recently, we identified a novel small molecule inhibitor, CU-3, that selectively inhibits the activity of the α isozyme. In addition, we newly obtained Compound A, which selectively and strongly inhibits type I DGKs (α, β, and γ). Read More

View Article
December 2018

Seizures as presenting symptom in patients with glioblastoma.

Epilepsia 2018 Dec 9. Epub 2018 Dec 9.

Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Objective: The clinical course and underlying molecular causes in patients with glioblastoma presenting with seizures are poorly understood. Here we investigated clinical features and carrier systems as well as a transaminase relevant in glutamate homeostasis in patients with glioblastoma.

Methods: We performed a retrospective analysis of our clinical glioma database for clinical data during a 2-year period. Read More

View Article
December 2018

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.

Int J Cancer 2018 Dec 11. Epub 2018 Dec 11.

Institute for Refractory Cancer Research.

Hypermutagenesis refers to marked increase in the number of mutations due to continuous mutagenic process. Hypermutated tumors, have being found in several tumor types, are associated with inherited or acquired alterations in DNA repair pathways. Hypermutation has been observed in a subset of adult glioma patients as a direct result of temozolomide(TMZ)-induced mutagenesis. Read More

View Article
December 2018

FABP4 accelerates glioblastoma cell growth and metastasis through Wnt10b signalling.

Authors:
H-Y Li B-B Lv Y-H Bi

Eur Rev Med Pharmacol Sci 2018 Nov;22(22):7807-7818

Department of Neurosurgery, Dezhou People's Hospital, Dezhou, Shandong, China.

Objective: Glioblastomas are one of the most dangerous types of malignancies because of their metastatic capacity and challenge to treat with chemotherapy or radiotherapy. Hence, detailed research to explain the molecular mechanisms of glioblastoma metastasis is crucial to improve glioblastoma treatment.

Patients And Methods: The expression level of fatty acid-binding protein 4 (FABP4) in glioblastoma cell lines and tissues was detected by Western blotting and quantitative Real-time polymerase chain reaction (qRT-PCR) assays. Read More

View Article
November 2018
1 Read

Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.

J Neurooncol 2018 Dec 10. Epub 2018 Dec 10.

Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Purpose: There are no widely accepted MRI markers that predict treatment outcomes of bevacizumab among patients with recurrent glioblastoma (GB). We aimed to determine if conventional MRI features of recurrent GB predict survival of patients receiving bevacizumab.

Methods: Patients with recurrent GB were retrospectively included if they received bevacizumab monotherapy between 2008 and 2017 after failure of standard treatment. Read More

View Article
December 2018
1 Read

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.

J Neurooncol 2018 Dec 9. Epub 2018 Dec 9.

Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM.

Methods: We used the FoundationOne® comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM. Read More

View Article
December 2018

Tropomyosin Tpm 2.1 loss induces glioblastoma spreading in soft brain-like environments.

J Neurooncol 2018 Dec 9. Epub 2018 Dec 9.

Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, 2145, Australia.

Introduction: The brain is a very soft tissue. Glioblastoma (GBM) brain tumours are highly infiltrative into the surrounding healthy brain tissue and invasion mechanisms that have been defined using rigid substrates therefore may not apply to GBM dissemination. GBMs characteristically lose expression of the high molecular weight tropomyosins, a class of actin-associating proteins and essential regulators of the actin stress fibres and focal adhesions that underpin cell migration on rigid substrates. Read More

View Article
December 2018

High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.

Mol Med Rep 2018 Dec 3. Epub 2018 Dec 3.

Department of Neurosurgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China.

Actin‑like protein 8 (ACTL8) is a member of the cancer‑testis antigens (CTA) family, which is mainly localized in the cytoplasm and generally expressed in the testis. The association between ACTL8 and various types of cancer, including glioblastoma and breast cancer, has previously been demonstrated. However, whether ACTL8 is involved in the development of head and neck squamous cell carcinoma (HNSCC) remains unknown. Read More

View Article
December 2018

A HYPOTHESIS OF RADIORESISTANCE AND CELL-SURVIVAL CURVE SHAPE BASED ON CELL-CYCLE PROGRESSION AND DAMAGE TOLERANCE.

Radiat Prot Dosimetry 2018 Dec 11. Epub 2018 Dec 11.

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany.

Exponential survival curves of early-passage human fibroblasts challenge classic biophysical models of cell inactivation. Thus, X-ray doses of 2-4 Gy inactivate normal, human skin fibroblasts in spite of negligible residual double-strand breaks. By contrast, radioresistant p53-mutant U251 glioblastoma cells proliferate in spite of residual damage. Read More

View Article
December 2018

A COMPARISON BETWEEN X-RAY AND CARBON ION IRRADIATION IN HUMAN NEURAL STEM CELLS.

Radiat Prot Dosimetry 2018 Dec 11. Epub 2018 Dec 11.

Department of Physics, University of Pavia, via Bassi 6, Pavia, Italy.

Glioblastoma multiforme (GBM) is characterized by a poor prognosis and a median survival of ~12-18 months. GBM is usually managed by neurosurgery followed by both chemotherapy and radiotherapy. Since GBM develops resistance to conventional therapies, treatment with C-ions is promising to completely eradicate the tumoural mass. Read More

View Article
December 2018

Immunogenetics of glioblastoma: the future of personalized patient management.

NPJ Precis Oncol 2018 4;2:27. Epub 2018 Dec 4.

Inova Neuroscience and Spine Institute, Inova Health Systems, Falls Church, VA USA.

The prognosis of glioblastoma has changed little over the past two decades, with only minor improvements in length of overall survival through the addition of temozolomide (temodal) to standard of care and the recommended use of alternating electric field therapy (optune) to newly diagnosed patients. In an effort to define novel therapeutic targets across molecularly heterogeneous disease subgroups, researchers have begun to uncover the complex interplay between epigenetics, cell signaling, metabolism, and the immunosuppressive tumor microenvironment. Indeed, IDH mutations are now recognized as a defining differential factor not only influencing global hypermethylation and patient prognosis but also degree of immune infiltration within individual tumors. Read More

View Article
December 2018
3 Reads

Opening the Blood-Brain Barrier and Improving the Efficacy of Temozolomide Treatments of Glioblastoma Using Pulsed, Focused Ultrasound with a Microbubble Contrast Agent.

Biomed Res Int 2018 11;2018:6501508. Epub 2018 Nov 11.

Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Objective: To explore the effects of pulsed, focused, and microbubble contrast agent-enhanced ultrasonography (mCEUS) on blood-brain barrier (BBB) permeability and the efficacy temozolomide for glioblastoma.

Methods: Wistar rats (n = 30) were divided into three groups (n = 10 per group) to determine optimal CUES conditions for achieving BBB permeability, as assessed by ultrastructure transmission electron microscopy (TEM) and western blot assays for the tight junction protein claudin-5. Optimized mCEUS effects on BBB permeability were subsequently confirmed with Evans blue staining (2 groups of 10 rats). Read More

View Article
November 2018

Tumor treating fields increases membrane permeability in glioblastoma cells.

Cell Death Discov 2018 5;4:113. Epub 2018 Dec 5.

1Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Room E150, 318 Campus Drive West, Stanford, CA 94305 USA.

Glioblastoma is the most common yet most lethal of primary brain cancers with a one-year post-diagnosis survival rate of 65% and a five-year survival rate of barely 5%. Recently the U.S. Read More

View Article
December 2018
1 Read

Nutritional stress reprograms dedifferention in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: a stochastic model of cancer stem cells.

Cell Death Discov 2018 5;4:110. Epub 2018 Dec 5.

1Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology (IICB), 4, Raja S.C. Mullick Road, Jadavpur, Kolkata, 700032 India.

The emergence and maintenance of cancer stem-like cells (CSCs) are usually governed by tumor niche. Tumor niche always provides metabolic challenges to cancer cells and CSCs mostly because of tissue hypoxia. However, the role of micro-environmental nutritional stress (NS) in dedifferentiation of cancer cells is poorly defined. Read More

View Article
December 2018

Inducing a Transient Increase in Blood Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme.

ACS Nano 2018 Dec 11. Epub 2018 Dec 11.

The blood brain barrier (BBB) selectively controls the passage of endogenous and exogenous molecules between systemic circulation and the brain parenchyma. Nano-carrier based drugs such as liposomes and nanoparticles are an attractive prospect for cancer therapy since they can carry a drug payload and be modified to improve targeting and retention at the desired site. However, the BBB prevents most therapeutic drugs from entering the brain, including physically restricting the passage of liposomes and nanoparticles. Read More

View Article
December 2018

CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo.

Cancer Manag Res 2018 15;10:5747-5758. Epub 2018 Nov 15.

Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China,

Background: Glioblastoma multiforme (GBM) remains to be one of the top lethal cancer types for adult to date. Current GBM therapies suffer greatly from the highly heterogeneous and adaptable nature of GBM cells, indicating an urgent need of alternative therapeutic options. In this study, we focused on identifying novel epigenetic targeted strategy against GBM. Read More

View Article
November 2018

Transcriptome and protein interaction profiling in cancer cells with mutations in histone H3.3.

Sci Data 2018 Dec 11;5:180283. Epub 2018 Dec 11.

Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center, Gyeonggi-do, Republic of Korea.

Mutations of histone variant H3.3 are highly recurrent in childhood glioblastoma and in young adults with Giant Cell Tumor of the Bone (GCTB). The heterozygotic representation of the mutations in the tumors, and with potential histone H3 and H3. Read More

View Article
December 2018

Gamma knife radiosurgery for local recurrence of glioblastoma.

Neuro Endocrinol Lett 2018 Oct 12;39(4):281-287. Epub 2018 Oct 12.

Department of Medical Physics, Na Homolce Hospital, Prague, Czech Republic.

Objective: Local recurrence of glioblastoma is observed in most patients after standard oncologic treatment (surgery, chemotherapy and radiotherapy). Stereotactic radiosurgery with the Leksell Gamma Knife (SRS with LGK) was used to treat recurrent tumors in selected cases, and retrospective analysis of treatment outcome was performed.

Methods: Altogether 126 patients were treated for glioblastoma at our center from 1992-2014. Read More

View Article
October 2018

High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway.

Med Sci Monit 2018 Dec 9;24:8916-8924. Epub 2018 Dec 9.

Department of Geriatric Medicine, Jinan Central Hospital of Shandong University, Jinan, Shandong, China (mainland).

BACKGROUND As a nuclear protein and a secreted protein, HMGB1 is involved in many cellular processes such as proliferation, transcription, and inflammation. The overexpression of HMGB1 in various types of cancers is reported, but its clinical significance and prognostic value in glioblastoma multiforme (GBM) has not been well defined. MATERIAL AND METHODS The expression of HMGB1 in 116 patients with GBM was investigated with immunohistochemistry, and was detected with qRT-PCR in 12 pairs of tumor tissues and adjacent tissues. Read More

View Article
December 2018
1 Read

Oxidative stress: the lowest common denominator of multiple diseases.

Neural Regen Res 2019 Feb;14(2):238-241

Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, University Hospital Essen, Essen, Germany.

Oxygen is essential to the human life and life of all aerobic organisms. The complete oxidation of nutrients for the biological energy supply is one of the most important prerequisites for the formation of higher life forms. However, cells that benefit from oxidative respiration also suffer from reactive oxygen species because they adapted to oxygen as an energy source. Read More

View Article
February 2019
0.234 Impact Factor

Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.

Cancer Biomark 2018 Nov 26. Epub 2018 Nov 26.

College of Physical Education, Yan'an University, Yan'an, Shaanxi 716000, China.

Background: It is well known that some circulating microRNAs (miRNAs) are highly stable and might serve as promising biomarkers for many types of human cancer including glioblastoma (GBM). However, the potential clinical significance of serum miR-100 in GBM remained unknown.

Objective: We aimed to detect the expression level of serum miR-100 in patients with GBM and assess its potential diagnostic and prognostic value. Read More

View Article
November 2018

Mobile phone use and incidence of brain tumour histological types, grading or anatomical location: a population-based ecological study.

BMJ Open 2018 Dec 9;8(12):e024489. Epub 2018 Dec 9.

Australian Centre for Electromagnetic Bioeffects Research, Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia.

Objective: Some studies have reported increasing trends in certain brain tumours and a possible link with mobile phone use has been suggested. We examined the incidence time trends of brain tumour in Australia for three distinct time periods to ascertain the influence of improved diagnostic technologies and increase in mobile phone use on the incidence of brain tumours.

Design: In a population-based ecological study, we examined trends of brain tumour over the periods 1982-1992, 1993-2002 and 2003-2013. Read More

View Article
December 2018

Drak/STK17A drives neoplastic glial proliferation through modulation of MRLC signaling.

Cancer Res 2018 Dec 10. Epub 2018 Dec 10.

Department of Pharmacology, Emory University

Glioblastoma (GBM) and lower grade gliomas (LGG) are the most common primary malignant brain tumors and are resistant to current therapies. Genomic analyses reveal that signature genetic lesions in GBM and LGG include copy gain and amplification of chromosome 7, amplification, mutation, and overexpression of receptor tyrosine kinases (RTK) such as EGFR, and activating mutations in components of the PI-3 kinase (PI3K) pathway. In Drosophila melanogaster, constitutive co-activation of RTK and PI3K signaling in glial progenitor cells recapitulates key features of human gliomas. Read More

View Article
December 2018

Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma.

Neoplasia 2018 Dec 5;21(1):106-116. Epub 2018 Dec 5.

National Centre for Cell Science (NCCS), SP Pune University Campus, Ganeshkhind, Pune, 411007, India. Electronic address:

Glioblastoma (GBM) is one of the most aggressive and lethal types of brain tumor. Despite the advancements in conventional or targeted therapies, median survival of GBM patients is less than 12 months. Amongst various signaling pathways aberrantly activated in glioma, active Wnt/β-catenin signaling pathway is one of the crucial oncogenic players. Read More

View Article
December 2018

Whole transcriptome sequencing analyses of DHA treated glioblastoma cells.

J Neurol Sci 2018 Nov 22;396:247-253. Epub 2018 Nov 22.

Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing 211166, China; Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing 211166, China. Electronic address:

Glioblastoma (GBM) is a typical malignant tumor, and there are no effective drugs capable of improving patient survival. Docosahexaenoic acid (DHA), a nutrient essential to animal health and neurodevelopment, exerts an anticancer effect in several types of cancer. However, the function of DHA in GBM is still unclear. Read More

View Article
November 2018
1 Read

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.

Cancer Lett 2018 Dec 4. Epub 2018 Dec 4.

Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin, 300052, China. Electronic address:

Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM). Here, we show that PLK4 affects TMZ sensitivity by regulating the IKBKE/NF-κB axis. The mRNA level of PLK4 was significantly associated with glioma grade progression and inversely correlated with overall survival (OS) in patients with high-grade gliomas (HGG). Read More

View Article
December 2018

Non-thermal plasma-activated medium modified metabolomic profiles in the glycolysis of U251SP glioblastoma.

Arch Biochem Biophys 2018 Dec 5;662:83-92. Epub 2018 Dec 5.

Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa, Nagoya, 484-8603, Japan; Plasma Medical Science Global Innovation Center, Nagoya University, Furo-cho, Chikusa, Nagoya, 484-8601, Japan; Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa, Nagoya, 484-8601, Japan.

Non-equilibrium atmospheric pressure plasma (NEAPP) is a mixture of radicals, electrons, anions, cations and light at near body temperature. Plasma-activated medium (PAM) is realized using NEAPP provided by engineered devices and irradiated to a cell culture medium for a period of 600 s. Glioblastoma cells U251SP cultivated in PAM previously indicated that antitumor effects induced PAM-specific apoptotic cell-death. Read More

View Article
December 2018

Glioblastoma in a patient with tuberous sclerosis.

J Clin Neurosci 2018 Oct 24. Epub 2018 Oct 24.

Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia.

Tuberous sclerosis complex (TSC) is a multisystem, autosomal dominant disorder with a wide clinical spectrum. The most common brain tumor associated with TSC is the low grade subependymal giant cell astrocytoma. Reports of high grade primary brain tumors in patients with TSC are rare. Read More

View Article
October 2018

TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways.

Biochim Biophys Acta Gen Subj 2018 Dec 5. Epub 2018 Dec 5.

Division of Medical Genetics, IRCCS Casa Sollievo della Sofferenza Hospital, Viale Padre Pio, 71013, San Giovanni Rotondo, Foggia, Italy. Electronic address:

Background: We recently reported TRIM8, encoding an E3 ubiquitin ligase, as a gene aberrantly expressed in glioblastoma whose expression suppresses cell growth and induces a significant reduction of clonogenic potential in glioblastoma cell lines.

Methods: we provided novel insights on TRIM8 functions by profiling the transcriptome of TRIM8-expressing primary mouse embryonal neural stem cells by RNA-sequencing and bioinformatic analysis. Functional analysis including luciferase assay, western blot, PCR arrays, Real time quantitative PCR were performed to validate the transcriptomic data. Read More

View Article
December 2018

EphA3 is up-regulated by epidermal growth factor and promotes formation of glioblastoma cell aggregates.

Biochem Biophys Res Commun 2018 Dec 6. Epub 2018 Dec 6.

Laboratory of Molecular Neurobiology, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan; Graduate School of Biostudies, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. Electronic address:

EphA3, a member of the Eph family of receptor tyrosine kinases, has been reported to be overexpressed in some human cancers including glioblastoma. Here, we found that expression of EphA3 is up-regulated in response to epidermal growth factor (EGF) stimulation and promotes formation of cell aggregates in suspension culture of glioblastoma cells. Suppression of EphA3 expression by short hairpin RNA-mediated knockdown or CRISPR/Cas9-mediated gene deletion inhibited EGF-induced promotion of cell aggregate formation, whereas overexpression of EphA3 promoted formation of cell aggregates in suspension culture. Read More

View Article
December 2018
1 Read

Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.

Clin Ther 2018 Dec 6. Epub 2018 Dec 6.

Department of Translational Research Promotion Incubation Center for Advanced Medical Science, Kyushu University, Fukuoka, Japan.

Purpose: In Japan, gene therapy and cellular therapy are categorized as regenerative medicine products based on the Pharmaceuticals and Medical Devices Law that was implemented in 2014. In this new law, regenerative medicine products were newly defined, and a conditional and term-limited approval system for regenerative medicine products was instituted. In addition, the Ministry of Health, Labour and Welfare instituted the SAKIGAKE (meaning pioneer or forerunner in Japanese) designation system in 2015. Read More

View Article
December 2018
1 Read

Identification of the shortest splice variant of Dp71, together with five known variants, in glioblastoma cells.

Biochem Biophys Res Commun 2018 Dec 4. Epub 2018 Dec 4.

Research Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe, 651-2180, Japan; KNC Department of Nucleic Acid Drug Discovery, Faculty of Rehabilitation, Kobe Gakuin University, Nishi, Kobe 651-2180, Japan. Electronic address:

Background: Dystrophin Dp71 mRNA is produced from the most distal alternative promoter of the DMD gene, mutations in which cause Duchenne muscular dystrophy (DMD). Dp71 is characterized by a wide variety of splice variants. In addition to being associated with cognitive disturbance in patients with DMD, Dp71 may also play a role in tumorigenesis. Read More

View Article
December 2018

[Photodynamic therapy for the treatment of glioblastoma in neurosurgery].

Med Sci (Paris) 2018 Nov 10;34(11):901-903. Epub 2018 Dec 10.

Université de Lille, Inserm, CHU de Lille, U1189 - ONCO-THAI - Thérapies laser assistées par l'image pour l'oncologie, 59000 Lille, France.

View Article
November 2018

1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation.

J Med Chem 2018 Dec 10. Epub 2018 Dec 10.

We report the synthesis, metabolism and biological evaluation of a series of 17 novel heterocyclic derivatives of isoCombretastatin-A4 and their structure-activity relationship. Among these derivatives, the most active compound 4f inhibited the growth of a panel of seven cancer cell lines with an IC50 in the low nanomolar range. In addition, 4f showed interesting activity against CA-4-resistant colon carcinoma cells and multidrug-resistant leukemia cells. Read More

View Article
December 2018
1 Read

Molecular mechanism of inhibition of acid ceramidase by carmofur.

J Med Chem 2018 Dec 7. Epub 2018 Dec 7.

Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors. Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available. In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented. Read More

View Article
December 2018
1 Read

Ligand density and linker length are critical factors for multivalent nanoparticle-receptor interactions.

ACS Appl Mater Interfaces 2018 Dec 6. Epub 2018 Dec 6.

Although there is a large number of studies available evaluating the therapeutic efficacy of targeted polymeric nanoparticles, little is known about the critical attributes that can further influence their uptake into target cells. In this study, varying cRGD ligand densities (0-100% surface functionalization) were combined with different PEG spacer lengths (2/3.5/5kDa) and the specific receptor binding of targeted core-shell structured PLGA/PLA-PEG nanoparticles was evaluated using αβ integrin overexpressing U87MG glioblastoma cells. Read More

View Article
December 2018
1 Read

Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy.

Mol Pharm 2018 Dec 6. Epub 2018 Dec 6.

A number of cancer-targeting peptide-drug conjugates (PDCs) have been explored as alternatives to antibody-drug conjugates (ADCs) for targeted cancer therapy. However, the much shorter circulation half-life of PDCs compared with ADCs in vivo has limited their therapeutic value and thus their translation into the clinic, highlighting the need to develop new approaches for extending the half-life of PDCs. Here, we report a new strategy for targeted cancer therapy of a PDC based on a molecular hybrid between an anti-hapten antibody and a hapten-labeled PDC. Read More

View Article
December 2018
3 Reads
4.384 Impact Factor

expression is influenced by astrocytoma grade and polymorphism.

J Cancer 2018 31;9(23):4496-4502. Epub 2018 Oct 31.

Laboratory of Molecular Neurooncology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.

Glial fibrillary acidic protein (GFAP) is an intermediate filament that provides mechanical support to astrocytes. is a single nucleotide polymorphism (SNP) located in the promoter region of the gene. The aim of this pilot study is to investigate expression at mRNA, protein levels and polymorphism in 50 different grade human astrocytoma samples. Read More

View Article
October 2018
3 Reads

NR2C2-uORF targeting UCA1-miR-627-5p-NR2C2 feedback loop to regulate the malignant behaviors of glioma cells.

Cell Death Dis 2018 Dec 5;9(12):1165. Epub 2018 Dec 5.

Department of Neurosurgery, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Accumulating evidence has highlighted the potential role of non-coding RNAs (ncRNAs) and upstream open-reading frames (uORFs) in the biological behaviors of glioblastoma. Here, we elucidated the function and possible molecular mechanisms of the effect of some ncRNAs and NR2C2-uORF on the biological behaviors of gliomas. Quantitative real-time PCR was conducted to profile the cell expression of lnc-UCA1 and microRNA-627-5p (miR-627-5p) in glioma tissues and cells. Read More

View Article
December 2018

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Acta Neuropathol Commun 2018 Dec 5;6(1):135. Epub 2018 Dec 5.

Activartis Biotech GmbH, Wilhelminenstraße 91/IIf, 1160, Vienna, Austria.

Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via "danger signals". The recent phase II "GBM-Vax" trial showed no clinical efficacy for Audencel as assessed with progression-free and overall survival in all patients. Read More

View Article
December 2018
3 Reads